GlassScriptPhysician profile
Davor Vugrin
NPI 1689746448
$386.77
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $89.35 · 2021: $96.50 · 2022: $17.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $62.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $57.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $53.29 | 2019-2021 | |
| Seagen INC. | $39.17 | 2020-2021 | |
| Astellas Pharma US INC | $30.41 | 2019-2020 | |
| Incyte Corporation | $29.00 | 2019-2020 | |
| Janssen Biotech, INC. | $28.89 | 2020-2021 | |
| Amgen INC. | $23.93 | 2019 | |
| Abbvie INC. | $19.72 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.07 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.69 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davor Vugrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.